Advertisement
Screener

OCUGEN, INC. (OCGN) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

OCUGEN, INC. Operating Expenses

OCUGEN, INC. (OCGN) reported Operating Expenses of $17.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2026-08-06

  • OCUGEN, INC. operating expenses for the quarter ending 2026-06-30 was $17.93M, a 18.22% increase year-over-year.
  • OCUGEN, INC. operating expenses for the quarter ending 2026-03-31 was $19.37M, a 21.21% increase year-over-year.
  • OCUGEN, INC. operating expenses for the quarter ending 2025-12-31 was $16.80M, a 15.05% increase year-over-year.
  • OCUGEN, INC. operating expenses for the quarter ending 2025-09-30 was $19.38M, a 34.67% increase year-over-year.
  • OCUGEN, INC. operating expenses for fiscal 2025 was $67.33M, a 14.48% increase from fiscal 2024.
  • OCUGEN, INC. operating expenses for fiscal 2024 was $58.81M, a 17.82% decline from fiscal 2023.
  • OCUGEN, INC. operating expenses for fiscal 2023 was $71.57M, a 21.84% decline from fiscal 2022.
  • OCUGEN, INC. operating expenses for fiscal 2022 was $91.56M, a 57.78% increase from fiscal 2021.
Period endOperating Expenses 3 monthOperating Expenses 3 month as first filedOperating Expenses 6 monthOperating Expenses 6 month as first filedOperating Expenses 9 monthOperating Expenses 9 month as first filedOperating Expenses 12 monthOperating Expenses 12 month as first filed
2026-06-30$17.93M
10-Q · filed 2026-08-06
$37.30M
10-Q · filed 2026-08-06
$54.11M
derived: sum of 3 quarters · filed 2026-08-06
$73.48M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$19.37M
10-Q · filed 2026-05-08
$36.17M
derived: sum of 2 quarters · filed 2026-05-08
$55.55M
derived: sum of 3 quarters · filed 2026-05-08
$70.72M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$16.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
$36.18M
derived: sum of 2 quarters · filed 2026-03-04
$51.35M
derived: sum of 3 quarters · filed 2026-08-06
$67.33M
10-K · filed 2026-03-04
2025-09-30$19.38M
10-Q · filed 2025-11-05
$34.55M
derived: sum of 2 quarters · filed 2026-08-06
$50.53M
10-Q · filed 2025-11-05
$65.13M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$15.17M
10-Q · filed 2026-08-06
$31.15M
10-Q · filed 2026-08-06
$45.75M
derived: sum of 3 quarters · filed 2026-08-06
$60.14M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$15.98M
10-Q · filed 2026-05-08
$30.59M
derived: sum of 2 quarters · filed 2026-05-08
$44.97M
derived: sum of 3 quarters · filed 2026-05-08
$61.56M
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31$14.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
$28.99M
derived: sum of 2 quarters · filed 2026-03-04
$45.58M
derived: sum of 3 quarters · filed 2026-03-04
$58.81M
10-K · filed 2026-03-04
2024-09-30$14.39M
10-Q · filed 2025-11-05
$30.98M
derived: sum of 2 quarters · filed 2025-11-05
$44.21M
10-Q · filed 2025-11-05
$57.14M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$16.59M
10-Q · filed 2025-08-04
$29.82M
10-Q · filed 2025-08-04
$42.75M
derived: sum of 3 quarters · filed 2025-08-04
$58.88M
derived: sum of 4 quarters · filed 2025-08-04
2024-03-31$13.23M
10-Q · filed 2025-05-09
$26.16M
derived: sum of 2 quarters · filed 2025-05-09
$42.29M
derived: sum of 3 quarters · filed 2025-05-09
$66.32M
derived: sum of 4 quarters · filed 2025-05-09
2023-12-31$12.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05
$29.06M
derived: sum of 2 quarters · filed 2025-03-05
$53.09M
derived: sum of 3 quarters · filed 2025-03-05
$71.57M
10-K · filed 2025-03-05
2023-09-30$16.13M
10-Q · filed 2024-11-14
$15.42M
10-Q · filed 2023-11-09
$40.16M
derived: sum of 2 quarters · filed 2024-11-14
$58.63M
10-Q · filed 2024-11-14
$56.91M
10-Q · filed 2023-11-09
$82.87M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$24.02M
10-Q · filed 2024-08-08
$23.73M
10-Q · filed 2023-08-21
$42.50M
10-Q · filed 2024-08-08
$41.48M
10-Q · filed 2023-08-21
$66.74M
derived: sum of 3 quarters · filed 2024-08-08
$92.31M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$18.48M
10-Q · filed 2024-05-14
$17.75M
10-Q · filed 2023-05-05
$42.71M
derived: sum of 2 quarters · filed 2024-05-14
$68.29M
derived: sum of 3 quarters · filed 2024-05-14
$90.51M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$24.23M
derived: 10-K 12 month − 10-K 9 month · filed 2024-04-16
$49.81M
derived: sum of 2 quarters · filed 2024-04-16
$72.03M
derived: sum of 3 quarters · filed 2024-04-16
$91.56M
10-K · filed 2024-04-16
$84.87M
10-K · filed 2023-02-28
2022-09-30$25.58M
10-K · filed 2024-04-16
$23.12M
10-Q · filed 2022-11-08
$47.80M
derived: sum of 2 quarters · filed 2024-04-16
$67.33M
10-K · filed 2024-04-16
$60.72M
10-Q · filed 2022-11-08
$81.90M
derived: sum of 4 quarters · filed 2024-04-16
2022-06-30$22.22M
10-K · filed 2024-04-16
$19.57M
10-Q · filed 2022-08-05
$41.75M
10-K · filed 2024-04-16
$37.60M
10-Q · filed 2022-08-05
$56.32M
derived: sum of 3 quarters · filed 2024-04-16
$67.11M
derived: sum of 4 quarters · filed 2024-04-16
2022-03-31$19.53M
10-K · filed 2024-04-16
$18.03M
10-Q · filed 2022-05-06
$34.10M
derived: sum of 2 quarters · filed 2024-04-16
$44.89M
derived: sum of 3 quarters · filed 2024-04-16
$70.50M
derived: sum of 4 quarters · filed 2024-04-16
2021-12-31$14.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$25.36M
derived: sum of 2 quarters · filed 2023-02-28
$50.97M
derived: sum of 3 quarters · filed 2023-02-28
$58.03M
10-K · filed 2023-02-28
2021-09-30$10.79M
10-Q · filed 2022-11-08
$36.40M
derived: sum of 2 quarters · filed 2022-11-08
$43.46M
10-Q · filed 2022-11-08
$47.26M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30$25.61M
10-Q · filed 2022-08-05
$32.67M
10-Q · filed 2022-08-05
$36.48M
derived: sum of 3 quarters · filed 2022-08-05
$46.66M
derived: sum of 4 quarters · filed 2022-08-05
2021-03-31$7.06M
10-Q · filed 2022-05-06
$10.87M
derived: sum of 2 quarters · filed 2022-05-06
$21.05M
derived: sum of 3 quarters · filed 2022-05-06
$24.46M
derived: sum of 4 quarters · filed 2022-05-06
2020-12-31$3.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$13.99M
derived: sum of 2 quarters · filed 2022-02-28
$17.40M
derived: sum of 3 quarters · filed 2022-02-28
$21.33M
10-K · filed 2022-02-28
$21.33M
10-K · filed 2021-03-19
2020-09-30$10.18M
10-Q · filed 2021-11-09
$10.18M
10-Q · filed 2020-11-06
$13.59M
derived: sum of 2 quarters · filed 2021-11-09
$17.52M
10-Q · filed 2021-11-09
$17.52M
10-Q · filed 2020-11-06
$21.80M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30$3.41M
10-Q · filed 2021-08-06
$3.41M
10-Q · filed 2020-08-14
$7.34M
10-Q · filed 2021-08-06
$7.34M
10-Q · filed 2020-08-14
$11.62M
derived: sum of 3 quarters · filed 2022-02-28
$14.33M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$3.93M
10-Q · filed 2021-05-07
$3.93M
10-Q · filed 2020-05-08
$8.21M
derived: sum of 2 quarters · filed 2022-02-28
$10.92M
derived: sum of 3 quarters · filed 2022-02-28
$13.25M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31$4.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$6.99M
derived: sum of 2 quarters · filed 2022-02-28
$9.32M
derived: sum of 3 quarters · filed 2022-02-28
$14.16M
10-K · filed 2022-02-28
$14.16M
10-K · filed 2020-03-27
2019-09-30$2.71M
10-Q · filed 2020-11-06
$5.04M
derived: sum of 2 quarters · filed 2020-11-06
$9.88M
10-Q · filed 2020-11-06
$15.57M
derived: sum of 4 quarters · filed 2020-11-06
2019-06-30$2.33M
10-Q · filed 2020-08-14
$3.06M
10-Q · filed 2019-08-09
$7.17M
10-Q · filed 2020-08-14
$11.11M
10-Q · filed 2019-08-09
$12.86M
derived: sum of 3 quarters · filed 2020-08-14
$15.26M
derived: sum of 4 quarters · filed 2020-08-14
2019-03-31$4.84M
10-Q · filed 2020-05-08
$8.05M
10-Q · filed 2019-05-15
$10.53M
derived: sum of 2 quarters · filed 2020-05-08
$12.93M
derived: sum of 3 quarters · filed 2020-05-08
$16.99M
derived: sum of 4 quarters · filed 2020-05-08
2018-12-31$5.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27
$8.09M
derived: sum of 2 quarters · filed 2020-03-27
$12.15M
derived: sum of 3 quarters · filed 2020-03-27
$16.14M
10-K · filed 2020-03-27
$30.11M
10-K · filed 2019-03-22
2018-09-30$2.40M
10-Q · filed 2019-11-12
$6.99M
10-Q · filed 2018-11-08
$6.46M
derived: sum of 2 quarters · filed 2019-11-12
$10.45M
10-Q · filed 2019-11-12
$20.37M
10-Q · filed 2018-11-08
$18.58M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$4.05M
8-K/A · filed 2019-10-07
$7.28M
10-Q · filed 2018-08-09
$8.05M
8-K/A · filed 2019-10-07
$13.38M
10-Q · filed 2018-08-09
$16.18M
derived: sum of 3 quarters · filed 2019-10-07
$21.89M
derived: sum of 4 quarters · filed 2019-10-07
2018-03-31$6.09M
10-Q · filed 2019-05-15
$12.13M
derived: sum of 2 quarters · filed 2019-05-15
$17.84M
derived: sum of 3 quarters · filed 2019-05-15
$24.21M
derived: sum of 4 quarters · filed 2019-05-15
2017-12-31$6.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22
$11.75M
derived: sum of 2 quarters · filed 2019-03-22
$18.12M
derived: sum of 3 quarters · filed 2019-03-22
$24.95M
10-K · filed 2019-03-22
2017-09-30$5.71M
10-Q · filed 2018-11-08
$12.09M
derived: sum of 2 quarters · filed 2018-11-08
$18.92M
10-Q · filed 2018-11-08
$26.82M
derived: sum of 4 quarters · filed 2018-11-08
2017-06-30$6.37M
10-Q · filed 2018-08-09
$13.20M
10-Q · filed 2018-08-09
$21.11M
derived: sum of 3 quarters · filed 2018-08-09
$27.76M
derived: sum of 4 quarters · filed 2018-08-09
2017-03-31$6.83M
10-Q · filed 2018-05-10
$14.74M
derived: sum of 2 quarters · filed 2018-05-10
$21.38M
derived: sum of 3 quarters · filed 2018-05-10
$29.34M
derived: sum of 4 quarters · filed 2018-05-10
2016-12-31$7.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
$14.55M
derived: sum of 2 quarters · filed 2018-03-15
$22.51M
derived: sum of 3 quarters · filed 2018-03-15
$30.31M
10-K · filed 2018-03-15
2016-09-30$6.65M
10-Q · filed 2017-11-09
$14.60M
derived: sum of 2 quarters · filed 2017-11-09
$22.40M
10-Q · filed 2017-11-09
$30.71M
derived: sum of 4 quarters · filed 2017-11-09
2016-06-30$7.96M
10-Q · filed 2017-08-10
$15.75M
10-Q · filed 2017-08-10
$24.07M
derived: sum of 3 quarters · filed 2017-08-10
$32.11M
derived: sum of 4 quarters · filed 2017-08-10
2016-03-31$7.80M
10-Q · filed 2017-05-11
$16.11M
derived: sum of 2 quarters · filed 2017-05-11
$24.15M
derived: sum of 3 quarters · filed 2017-05-11
$31.74M
derived: sum of 4 quarters · filed 2017-05-11
2015-12-31$8.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
$16.35M
derived: sum of 2 quarters · filed 2017-03-16
$23.95M
derived: sum of 3 quarters · filed 2017-03-16
$31.82M
10-K · filed 2017-03-16
2015-09-30$8.04M
10-Q · filed 2016-11-10
$15.63M
derived: sum of 2 quarters · filed 2016-11-10
$23.50M
10-Q · filed 2016-11-10
$30.04M
derived: sum of 4 quarters · filed 2016-11-10
2015-06-30$7.59M
10-Q · filed 2016-08-11
$15.47M
10-Q · filed 2016-08-11
$22.00M
derived: sum of 3 quarters · filed 2016-08-11
$36.95M
derived: sum of 4 quarters · filed 2016-08-11
2015-03-31$7.87M
10-Q · filed 2016-05-12
-$7.87M
10-Q · filed 2015-05-14
$14.41M
derived: sum of 2 quarters · filed 2016-05-12
$29.35M
derived: sum of 3 quarters · filed 2016-05-12
$35.36M
derived: sum of 4 quarters · filed 2016-05-12
2014-12-31$6.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10
$21.48M
derived: sum of 2 quarters · filed 2016-03-10
$27.49M
derived: sum of 3 quarters · filed 2016-03-10
$32.66M
10-K · filed 2016-03-10
2014-09-30$14.94M
10-Q · filed 2015-11-12
$20.95M
derived: sum of 2 quarters · filed 2015-11-12
$26.12M
10-Q · filed 2015-11-12
2014-06-30$6.01M
10-Q · filed 2015-08-12
$11.18M
10-Q · filed 2015-08-12
2014-03-31-$5.17M
10-Q · filed 2015-05-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
AGENUS INC (AGEN)United States$0.383B1.41
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Surrozen, Inc./DE (SRZN)United States$0.395B